Abstract

Are all cancers becoming rare? How will we cope with the increasing compartmentalization of cancers in an era of ever increasing data? We will discuss rare cancers in the context of clinical trials, exploring practical issues of trials design and collaboration on an international scale as well as exploring the successes and how they have been achieved